Evidence map›Paper›PMID 39595827›Full record

ReviewBrain sciences2024

Photobiomodulation as a Potential Treatment for Alzheimer's Disease: A Review Paper.

Miaomiao Wang, Deeba Dinarvand, Clement T Y Chan, Anatol Bragin, Lin Li

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Brain sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Miaomiao WangDepartment of Biomedical Engineering, University of North Texas, Denton, TX 76207, USA.
Deeba DinarvandDepartment of Biomedical Engineering, University of North Texas, Denton, TX 76207, USA.
Clement T Y ChanDepartment of Biomedical Engineering, University of North Texas, Denton, TX 76207, USA.
Anatol BraginDepartment of Neurology, University of California Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0003-1207-8481
Lin LiDepartment of Biomedical Engineering, University of North Texas, Denton, TX 76207, USA.

Funding

In Vivo Studies of the Epileptic HippocampusRF1NS033310 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ENGEL, JEROME NONE, STABA, RICHARD · 2023 to 2023
$3.6M
NIH HHS 1RF1NS033310-27S1NINDS NIH HHS RF1 NS033310
6 · The paper itself

Abstract

backgroundAlzheimer's disease (AD), the most prevalent form of dementia, is a leading neurodegenerative disorder currently affecting approximately 55 million individuals globally, a number projected to escalate to 139 million by 2050. Despite extensive research spanning several decades, the cure for AD remains at a developing stage. The only existing therapeutic options are limited to symptom management, and are often accompanied by adverse side effects. The pathological features of AD, including the accumulation of beta-amyloid plaques and tau protein tangles, result in progressive neuronal death, synaptic loss, and brain atrophy, leading to significant cognitive decline and a marked reduction in quality of life.

objectiveIn light of the shortcomings of existing pharmacological interventions, this review explores the potential of photobiomodulation (PBM) as a non-invasive therapeutic option for AD. PBM employs infrared light to facilitate cellular repair and regeneration, focusing on addressing the disease's underlying biomechanical mechanisms.

methodThis paper presents a comprehensive introduction to the mechanisms of PBM and an analysis of preclinical studies evaluating its impact on cellular health, cognitive function, and disease progression in AD.The review provides a comprehensive overview of the various wavelengths and application methods, evaluating their efficacy in mitigating AD-related symptoms.

conclusionsThe findings underscore the significant potential of PBM as a safe and effective alternative treatment for Alzheimer's disease, emphasizing the necessity for further research and clinical trials to establish its therapeutic efficacy conclusively.

Indexed as

Alzheimer’s disease (AD)non-invasive treatmentphotobiomodulation (PBM)

Identifiers

PMID39595827
PMCPMC11591719

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.